Where the category stands in May 2026 — what's available, who to trust, what costs what. 22-min read, medically reviewed.
Read the guideAn independent overview of the compounded-GLP-1 telehealth market and the providers we cover — market size, what the FDA changed, and an honest read on each.
View the provider overviewOverview & reviewsPrimers for newcomers and deep dives for the curious. The foundation articles are published; more are in the pipeline.
View all Learn articlesWhat compounded and branded semaglutide and tirzepatide actually cost, from each provider's own published pricing.
Where 503A/503B compounding stands after the 2025 shortage delistings — the dates that matter, with primary sources. Legal status here is dynamic; every claim is dated.
A working timeline, not legal advice. Dates and figures trace to primary sources (FDA, federal register, court filings) cited on the linked pages. Compounding rules are moving — recheck before acting.
For most of 2023–2024, mass-compounded semaglutide and tirzepatide rested on the FDA drug-shortage exemption. That basis has been withdrawn: the molecules came off the shortage list, the enforcement grace periods lapsed in 2025, and the FDA has now proposed excluding them from the 503B bulks list permanently. What remains is narrow, patient-specific 503A compounding. Full context: compounded vs branded peptides.